Patients with stable ischemic heart disease and diabetes have improved survival when risk factors such as lifestyle behaviors and glycated hemoglobin A1c level are controlled.
Being a younger age at diagnosis of type 2 diabetes is associated with greater risk for total mortality and mortality related to cardiovascular disease outcomes.
Pemafibrate is a safe and effective method for lowering triglyceride and cholesterol levels in patients with type 2 diabetes and hypertriglyceridemia.
Glycemic variability was the strongest independent predictive factor of midterm major adverse cardiac events in patients with diabetes and acute coronary syndrome.
Although congenital heart defects are more frequent in offspring of mothers with overweight or obesity, the relationship between maternal overweight and obesity and risk for complex and specific heart defects is not well defined.
Patients with type 2 diabetes treated with liraglutide experience a greater reduction in systolic BP if they have lower baseline continuous glucose monitoring values and higher diastolic BP.
People who do not have diabetes or cardiovascular disease but have high hemoglobin A1c variability tend to be at greater risk for major adverse cardiovascular events and all-cause mortality.
Type 2 diabetes is an independent risk factor for sudden cardiac arrest and death in patients with coronary artery disease with preserved ejection fraction.
Investigators examined the excess risk for heart failure in patients with type 2 diabetes and compared the risk with that in the general population without diabetes.
